Summary Overexpression of the multidrug resistance (mdrl) gene has been implicated in resistance to a number of the chemotherapeutic agents currently used in the treatment of bladder cancer (doxorubicin, vincristine and epirubicin). We report the development and validation of a quantitative assay for the determination of mdrl gene transcript levels based on reverse transcription and the polymerase chain reaction (PCR), sensitive to less than 2-fold variations in transcript levels. Using these techniques, mdrl mRNA levels were investigated in 32 primary untreated transitional cell carcinomas of the bladder. mdrl mRNA was detected in all samples, with levels varying between individual tumours over a 63-fold range. These variations were not associated with the proliferative status of the tumour. mdrl mRNA levels were significantly higher in poorly differentiated high-grade (G3) tumours than in well-and moderately differentiated low-grade (GI and G2) tumours (P = 0.0057). The results suggest that this relationship may extend to mdrl mRNA levels being an indicator of poor prognosis, as anticipated on the basis of the observed relationship to tumour stage and grade. No evidence was found to implicate mdrl mRNA levels as a predictor of tumour recurrence or progression. Given that mdrl mRNA levels are increased in a proportion of high-grade bladder tumours that are routinely subjected to chemotherapy, we discuss the possibility that mdrl mRNA levels may be clinically significant as determinants of chemotherapeutic response and outcome in bladder cancer.
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Cancer of the urinary bladder is the fifth most common malignancy in males of the western world, approximating to 16 new cases per 100,000 males per year in western populations (Davies, 1982) . Transitional cell carcinomas (TCCs) of the urothelium constitute more than 90% of urothelial malignancies (Raghavan, 1988) . Well-differentiated superficial tumours make up 60-65% of the bladder TCCs and may be treated by local resection with 5 year survival of 80% (Raghavan, 1988; Kiemeney et al., 1993) . However, the prognosis for patients presenting with muscle-invasive, dedifferentiated tumours is poor, with typical survival rates of 40-50% following combination radiotherapy and radical cystectomy (Skinner & Lieskovsky, 1984; Hendry, 1988) .
Systemic chemotherapy is increasingly being used in the treatment of invasive bladder cancer, with combination regimens proving the most successful. Using an MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) regimen, Sternberg et al. (1988) achieved a 67% response rate (37% complete) with median remission of over a year. Similarly, Harker et al. (1985) produced a 56% total (28% complete) response rate with median survival of 8 months using a CMV regimen. Both studies showed responses at all sites of the disease. However, it is clear that invasive tumours of the bladder are not wholly responsive to chemotherapy, with the majority of patients still dying of their disease. The reasons for this remain unclear -several cellular mechanisms have been described that may confer upon tumours resistance to many of the currently used chemotherapeutic drugs, of which the multidrug resistance (mdrl) gene has been the most widely studied to date.
Classical multidrug resistance is manifested by crossresistance to a number of functionally unrelated lipophilic drugs of little structural similarity, including the vinca alkaloids (vincristine, vinblastine) , the anthracyclines (doxorubicin, epirubicin), antibiotics (actinomycin D, mitomycin C) and taxol, and is thus implicated in resistance to a number of the agents currently used in the treatment of invasive bladder cancer. Acquisition of a multidrug resistance phenotype has been causally associated with expression of the mdrl gene, which encodes P-glycoprotein (PGP), a 170 kDa plasma membrane protein that functions as an energy-dependent drug efflux pump resulting in decreased drug accumulation (Endicott & Ling, 1989; Van der Bliek & Borst, 1989) . Cell line studies have shown good correlation between mdrl mRNA levels and the degree of multidrug resistance (Shen et al., 1986; Fojo et al., 1987; Chan et al., 1988; Noonan et al., 1990) . mdrl expression has been widely observed in many different human tumour and tissue types, with increased mdrl levels frequently observed at relapse following chemotherapy (Fojo et al., 1987; Goldstein et al., 1989; Noonan et al., 1990) . Intrinsic variation in mdrl expression levels may be an important determinant of tumour response, yet few studies have investigated variation of mdrl mRNA levels within a specific tumour type prior to treatment, or related this to factors such as tumour grade and survival. Undetectable or low levels of mdrl mRNA have been reported in both drugsensitive and drug-resistant tumours prior to chemotherapy, lying close to or below the detection limits of conventional methods (Goldstein et al., 1989; Noonan et al., 1990 Assay insensitivity coupled with the often limited sample material available from tumours has hampered the detection of what may be clinically significant levels of mdrl mRNA. To investigate whether such mdrl mRNA levels lie below these detection limits, we report the development and validation of an assay based on reverse transcription and the polymerase chain reaction (PCR) for use in the determination of mdrl mRNA levels in clinical samples. Using these methods we have determined the incidence of and variation in mdrl transcript levels in a series of untreated TCCs of the bladder, and investigated the relationship of these levels to tumour stage, grade and rate of proliferation, prognosis, survival, progression and recurrence. (Kuwazuru et al., 1990; Noonan et al., 1990) . We have also investigated the suitability of P2-M mRNA levels as an internal reference for the measurement of mdrl mRNA levels in bladder cancer.
Tumours and tissues TCC tumour samples obtained at resection or cystectomy were immediately snap frozen in liquid nitrogen and transferred to a -80°C freezer for storage. A portion of the sample was sent for histological assessment and the tumours were staged and graded according to UICC (1978) criteria. All samples described in this study had not received prior chemotherapy. Eleven out of 18 of the patients with invasive tumours (T2-T4) went on to undergo chemotherapy. Adrenal tissue was obtained from patients undergoing radical nephrectomy.
Care was taken to limit the proportion of the tumour sample contaminated by normal tissue. Because of their papillary growth pattern superficial tumours were readily removed without contamination from underlying normal tissue. Although the invasive tumours were more difficult to separate from the underlying lamina propria and muscle, contamination by normal tissue was minimised by only taking samples from the protruding mass of the tumour. Although it was difficult to ensure complete elimination of normal tissue from these samples, histological examination indicated an upper limit of 10-15% normal tissue.
Cell lines
Multidrug-resistant cell lines known to overexpress the mdrl gene and their parental controls were used for assay development and validation. All lines were tested and found to be mycoplasma negative.
The KK47 cell line was established from an untreated grade 1, stage Ta TCC of the bladder, from which the multidrug-resistant cell line KK47/ADM was derived by stepwise selection in increasing concentrations of doxorubicin (Kimiya et al., 1992) . Both lines were grown as monolayer cultures in complete minimum essential medium (MEM) at 37°C in a 5% carbon dioxide atmosphere, and subcultured weekly by harvesting with a 0.25% trypsin -0.02% EDTA solution and reseedingy at 3 x 106cells per 175 cm2 flask.
The small-cell lung cancer (SCLC) cell line NCI-H69P was derived from a patient who had previously received multidrug therapy. Its multidrug-resistant variant, H69/LX4, was derived by stepwise selection in doxorubicin (Twentyman et al., 1986) . Both lines were cultured in RPMI-1640 medium (Dutch modification) (Northumbria Biochemicals) supplemented with 10% fetal calf serum, L-glutamine (2 mM), penicillin (100 U ml-1) and streptomycin (100 jig ml-') at 37°C in a 5% carbon dioxide atmosphere. Doxorubicin (0.4 iLg ml-') was added to H69/LX4 cultures. Both lines were grown as non-adherent batch cultures, and resuspended in fresh medium every 4 days.
RNA extraction Total RNA was extracted from the remaining tumour tissue and cell lines using the RNAzol method (Chomzynski & Sacchi, 1987) . Briefly, in the case of solid tumours, tissue was pulverised in liquid nitrogen and rapidly lysed in a phenolguanidinium thiocyanate-i-mercaptoethanol mixture. Cell lines were harvested at 70% confluence by scraping in icecold phosphate-buffered saline (PBS) (KK47 and KK47/ ADM) or by centrifugation followed by washing in PBS (H69 and H69/LX4). Both methods preceded direct lysis as (Gibco BRL) . The reaction was allowed to proceed at 37°C for 1.5 h before termination by heating to IOOC for a further 5 min. Following synthesis, cDNA was purified by passage through a cDNA spun column containing Sephacryl S-300 (Pharmacia) to remove any remaining proteins, free nucleotides and random hexamers remaining from previous procedures. The second cDNA strand was synthesised by the extension of sequence-specific oligonucleotide primers in the first cycle of a subsequent polymerase chain reaction.
Optimisation of the polymerase chain reaction mdrl and P2-M primers chosen were those used by Noonan et al. (1990) . The mdrl primers distinguish between the mdrl and mdr2 gene sequences, and both the mdrl and P2-M primers span an intron to control against contamination by amplification of genomic DNA sequences. Primers to 18S rRNA were chosen using a computer program designed by Lowe et al. (1990) -ATGCTCTTAGCTGAGTGTCC and AACTACGACGGTATCTGATC (residues 763-782 and 1055-1074 respectively; Gonzalez & Schmickel, 1986 ). Primers were made on an oligonucleotide synthesiser (Model 392, Applied Biosystems). The primers yielded products of 167 base pairs (mdrl), 120 base pairs (02-M) and 311 base pairs (18S rRNA). For each set of primers, a series of fixed-condition PCR reactions were performed employing a fixed concentration of input cDNA. The absolute magnesium chloride concentration was varied in 0.5 mM steps in the 0-5 mM range. The optimal magnesium chloride concentrations were determined to be: mdrl, 2.5 mM; P2-M, 3 mM; and 18S rRNA, 1 mM.
Determination of mdrl mRNA levels Typical PCR reaction yields for various cDNA inputs are shown in Figure 1 . An initial range-finding experiment was performed to determine the range of serial cDNA dilutions over which PCR amplification is linear for each target species. Serial cDNA dilutions for each species are simultaneously and independently amplified over 25 PCR cycles (94°C for 1 min, 56°C for 1 min, 72°C for 1 min) using otherwise fixed reaction conditions. Following amplification, 10 gil aliquots were analysed by electrophoretic separation on 12% polyacrylamide gels at 100 V for 1.5 h. Gels were dried under heat and vacuum and the radioactively labelled PCR products detected and analysed using a PhosphorImager (Molecular Dynamics). A typical autoradiograph image of the separated prod,ucts is shown in Figure 1 . For each species, the amount of PCR product (measured as incorporated radioactivity) was plotted against input cDNA dilution (see Figure 2) . Regression analysis was performed on the points constituting the linear range of amplification for each species. The ratio of input total cDNA concentrations (X,/X2 in Figure 3 ) for a given yield in the linear range of amplification is a measure of the ratio of cDNA concentrations present for each species. This is equal to the slope ratio (M1/M2) for the regression lines on the linear part of the yield curve (see Figure 3) . Thus, mdrl mRNA levels were expressed as an mdrl/18S ratio. Subsequent replicates were performed using only four serial dilutions (lying within the predefined linear amplification ranges) per species. Analysis was performed in triplicate on all samples. A linear regression correlation coefficient (r2) of greater than 0.95 was used as the criterion for accepting data that fell within the linear range of amplification.
Determination of tumour proliferative status -MIBI analysis
The monoclonal antibody MIBI reacts with the human nuclear cell proliferation-associated antigen recognised by the monoclonal antibody, Ki67, that is expressed in all active parts of the cell cycle (Cattoretti et al., 1992) . The extent of MIB1 staining was thus used to assess the proliferative status of a tissue.
Paraffin sections (4 pim thick) were taken and dewaxed in xylene prior to rehydration through alcohol and water. Sections were treated with 0.1 M citrate buffer (pH 6.0) and microwaved for 20 min. Endogenous peroxidase activity was blocked by prior treatment with 3% hydrogen peroxide. The sections were then rinsed in Tris-buffered saline (TBS pH 7.6) cDNA dilution 10°10-1 10-2 10-3 10-4 for 2 min, followed by normal goat serum (Life Science To examine any influence that PCR amplification efficiency may have on our results, efficiency studies were performed on four different tissue types with varying mdrl/18S levels. Figure 4a and b shows the results for a typical bladder tumour RNA sample as an example. Reaction efficiency was calculated using the formula Nn = N_ I (1 + a), where Nn is the amount of product after the nth cycle, n is the cycle number and a is the efficiency. 18S rRNA was amplified with the greatest efficiency, followed by mdrl then P2-M (Figure 4b ). This order of efficiency remained constant for tissues analysed. For each product species, the absolute amplification efficiency showed some variation between samples, however relative amplification efficiencies remained consistent between samples, irrespective of tissue type or level of mdrl expression (Table I) . The maximum efficiency range corresponds to the linear range of amplification, and its position is dependent on the input cDNA concentration. The assay that we have described utilises cDNA concentrations in the range that gives linear amplification over 25 PCR cycles. ;sis shown in analysis, regardless of treatment received. Log-rank survival as defined in analysis (Peto et al., 1977) showed no significant difference oduced show (P = 0.36) between survival for the groups of tumours with near phase of high and low mdrl mRNA levels ( Figure 6 ). However, con- 24  48  72  96  120  144  168  192  12  36  60  84  108  132  156  180  204 Time (months) Figure 6 Log-rank survival curves for groups of patients with tumours expressing high and low mdrl mRNA levels. Each death is represented by a vertical drop on the graph. Surviving patients are shown as a vertical tick on the graph representing the end of their current follow-up period. The log-rank test gave P = 0.36 for no difference in survival rates between the low-(-) and high-mdrl ( ) mRNA groups (see also text).
mRNA tumours, which was marginally significant P= 0.07).
Relationship between mdrl mRNA levels and tumour proliferative status The percentage of proliferating cells within the tumours studied (those displaying the Ki67 antigen) did not correlate with their mdrl/18S ratios (r = 0.06, n = 24).
Other mdrl mRNA determinations As part of general method validation and to put our data into a broader context, mdrl/18S ratios were also determined for some other tissues and cell lines with known low and high levels of mdrl expression. Adrenal tissue had an mdrl mRNA level (mdrl/18S = 2.00 x 10-4) approximately 27 times higher than the mean level of expression in bladder tumours. Hyperexpression (1.58 x 10-3) was detected in the mdr SCLC cell line H69/LX4, while no mdrl expression could be quantified in its drug-sensitive parent line H69 at 25 PCR cycles. The mdr bladder tumour cell line KK47/ADM had 157-fold overexpressed mdrl mRNA levels (mdrl/1 8S ratio 3.88 x 10-4), compared with levels of 2.46 x 10-6 in its parental line KK47.
Discussion
The PCR-based transcription assay Measurement of expression relative to an endogenous internal reference avoids the need for addition and quantification/ titration of an external reference standard, or the manipulation of products post amplification to distinguish them (e.g. the presence of restriction enzyme cleavage site in a synthetic reference standard), both strategies being among those previously described (Becker-Andre & Hahlbrock, 1989; Wang et al., 1989) . 18S rRNA is widely used to control for equal loading and transfer in Northern blot methods for RNA analysis. Good evidence exists for the use of rRNA (of which 18S rRNA is one component) as a reference. While variations in total rRNA levels per cell do occur, these are usually accompanied by an equal fluctuation in total mRNA levels (Johnson et al., 1976) . Hirsch (1967) observed consistent rRNA levels (80% of total) in normal rat liver, fasted rat liver (with a 50% reduction in total RNA content) and rapidly dividing rat hepatoma. P2-Microglobulin has been commonly used as an internal reference for the determination of mdrl transcript levels in PCR-based studies (Kuwazuru et al., 1990; Noonan et al., 1990 Based on the typical standard error of 23% of the mean of three replicates, this assay is capable of discriminating 1.6-fold differences in mRNA levels between samples at the 95% confidence level. The reproducibility studies based on three independent batch cultures, RNA extractions and cDNA syntheses similarly indicate that mdrl mRNA levels from three independent analyses of a given sample fall within a 2.5-fold range, however this may overestimate the situation since the batch cultures were not harvested at uniform cell densities and may also be prone to differing culture conditions, both of which may affect cellular mRNA levels. These limits are small compared with the 63-fold variation that we have observed in mdrl mRNA levels between individual tumour samples.
For the assay as described, 10lg of total RNA yields sufficient cDNA to perform at least five replicates of the assay, although there are various ways in which the sensitivity could be further increased if necessary. In com- parison, Northern blot analysis may require 10-20 pig of RNA for a single analysis. In the clinical situation, in which sample material is often limited, this may not allow for a repeat analysis. This method offers notable improvements in sensitivity over conventional methods, detecting mdrl transcript in all samples analysed, whereas previous studies using Northern blot analysis have only detected mdrl mRNA positivity in one of six (<17%) bladder tumours (Goldstein et al., 1989 (Goldstein et al., 1989; Zastawny et al., 1993) . Recently it has been demonstrated that wildtype p53 protein represses human mdrl promoter activity while mutant forms (cysteine 135 to serine) of the p53 protein enhance mdrl transcription (Zastawny et al., 1993) , thus defining a possible mechanism for increased mdrl mRNA levels in high-grade untreated bladder tumours, in which frequent p53 alterations have been reported (Lunec & Mellon, 1994 Relationships between mdrl mRNA levels and prognosis/survival Our results demonstrate that mdrl mRNA levels are clearly elevated in high-grade bladder tumours. A recent immunohistochemistry study also showed increased levels of the mdrl gene product, P-glycoprotein, in high-stage neuroblastomas (Chan et al., 1991) . Thus, evidence exists for mdrl mRNA and P-glycoprotein levels being a marker of tumour aggression (invasiveness and dedifferentiation). However, the majority of studies are conducted at the protein level, with this study to our knowledge being the first to report such an association at the mRNA level. Other studies investigating P-glycoprotein levels in bladder cancer (Benson et al., 1991; Naito et al., 1992) have proved inconclusive, showing no clear relationships with stage and grade.
The population distribution of mdrl/18S ratios observed in bladder tumours has allowed us to distinguish groups of high-and low-expressing tumours for use in survival analysis.
Log-rank tests showed no significant difference in survival for either group of tumours (Figure 6) , however this analysis is complicated by the problem of non-uniform patient treatment and follow-up times. The analysis by Fisher's exact test based on proportions of survivors alone indicates a significant relationship between high mdrl mRNA levels and poor survival. Other studies have similarly reported high mdrl expression to be an indicator of adverse prognosis and poor survival in untreated tumours; at the protein level in softtissue sarcomas (Chan et al., 1990) , breast carcinoma (Verrelle et al., 1991) , neuroblastoma (Chan et al., 1991) and nonlymphoblastic leukaemia (Campos et al., 1992 ), and at the message level in acute myeloid leukaemia (Pirker et al., 1991) . Our results suggest that it may be worth investigating further the prognostic potential of mdrl mRNA levels in bladder cancer. It may be interesting to compare mdrl mRNA with other known prognostic factors using samples from patient groups undergoing either uniform treatment strategies or receiving no treatment.
We have demonstrated that mdrl mRNA levels are raised in many of the high-grade, invasive bladder tumours that are commonly treated using chemotherapy, and suggest that the 34-fold variation in mdrl mRNA levels observed between individual high-grade tumours could be a significant determinant of their chemotherapeutic response. This is supported by in vitro studies which show that even small variations in mdrl mRNA levels, within the range we have observed, result in significant differences in drug response (Noonan et al., 1990) . To evaluate the role of pretreatment mdrl mRNA levels in the determination of chemotherapeutic outcome, full prospective studies have been initiated involving uniform treatment regimens with pre-and post-chemotherapy tumour biopsies. This will also test whether mdrl mRNA levels are increased following treatment, as has been reported in some tumour systems (Fojo et al., 1987; Noonan et al., 1990 
